What factors besides disease progression would lead you to de-intensify or change MM therapy for a patient with ongoing response?
In your experience, do certain regimens have more cumulative toxicity, financial impact, or patient convenience factors?
Answer from: Medical Oncologist at Academic Institution
After initial therapy (which may or may not include an autologous stem cell transplant), patients are generally on continuous/maintenance therapy with e.g. lenalidomide as the most common regimen. Most patients do well on this as maintenance. However, loose stools are probably the most common compla...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Completely agree with Dr. @Andrew J. Yee on all fronts. Assuming this question specifically pertains to lenalidomide maintenance, I'll also add:
1) If you're unsure whether your patient's symptoms are lenalidomide-related or not during maintenance, the difference between continuous lenalidomid...
Answer from: Medical Oncologist at Academic Institution
Alterations in therapy will be dictated by disease response as well as toxicity related to the therapy period. If the patient is not having a good disease response or if there is evidence of disease progression, one should consider changing the regimen completely with the introduction of new drugs i...